Synthon B.V.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
1
Ending by 2030
Sep 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 19, 2027The maintenance fee for Modified release tablet composition comprising mirabegron (US 10,478,399) comes due May 19, 2027. Unpaid by Nov 19, 2027, it lapses early.
- 3 fees due Jul 2 to 28, 2027 · next Jul 2
- 1 fee due Aug 27, 2027The maintenance fee for Pharmaceutical composition comprising Lenvatinib mesylate (US 11,911,509) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
- 1 fee due Sep 17, 2027The maintenance fee for Pharmaceutical composition comprising sacubitril and valsartan (US 10,588,892) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,655,798 | Process of making crystalline Type II aripiprazole In force · From the USPTO record | In force | From the USPTO record | |
| US 8,529,949 | Pharmaceutical tablets of crystalline type II aripiprazole In force · From the USPTO record | In force | From the USPTO record | |
| US 9,702,866 | Glatiramer acetate human monocytic cell line-based potency assay In force · From the USPTO record | In force | From the USPTO record | |
| US 9,617,313 | Process for purifying a polymer mixture In force · From the USPTO record | In force | From the USPTO record | |
| US 10,188,655 | Liquid pharmaceutical composition comprising pemetrexed In force · From the USPTO record | In force | From the USPTO record | |
| US 10,272,090 | Liquid Pharmaceutical Composition Comprising Pemetrexed In force · Low confidence | In force | Low confidence | |
| US 10,259,805 | Process for Making Crystalline Form a of Gefitinib In force · High confidence | In force | High confidence | |
| US 10,543,174 | Modified release tablet composition comprising mirabegron In force · From the USPTO record | In force | From the USPTO record | |
| US 10,894,839 | Process for making Sugammadex In force · From the USPTO record | In force | From the USPTO record | |
| US 10,478,399 | Modified release tablet composition comprising mirabegron In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 33: 1 patent in force now held by others · 69 lapsed for an unpaid fee · 7 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 pending · 3 abandoned · 20 no status recorded